Investigating the link between advanced glycation products and vascular complications in type 1 diabetes
Advanced Glycation Products and the Incidence of Vascular Complications in Type 1 Diabetes: DIABAGE Study After More Than 5 Years
CHU de Reims · NCT06458088
This study looks at how certain substances in the blood might be linked to blood vessel problems in people with type 1 diabetes over five years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 196 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CHU de Reims (other) |
| Locations | 1 site (Reims) |
| Trial ID | NCT06458088 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the occurrence of vascular complications in patients with type 1 diabetes who were previously part of the DIABAGE study. It will follow these patients for at least five years to assess both micro and macroangiopathic events. The study will also investigate the predictive value of initial measurements of advanced glycation end products (AGEs) and their correlation with HbA1c values over time. Participants will undergo clinical examinations and biological check-ups as part of their routine follow-up at the Reims University Hospital.
Who should consider this trial
Good fit: Ideal candidates are individuals with type 1 diabetes who were previously included in the DIABAGE study and are receiving follow-up care at the Reims University Hospital.
Not a fit: Patients who are not part of the initial DIABAGE study or those who refuse to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of how advanced glycation products contribute to vascular complications in type 1 diabetes, potentially leading to improved management strategies.
How similar studies have performed: Previous studies have indicated a significant association between advanced glycation end products and vascular complications, suggesting that this approach has been explored with some success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Inclusion in initial DIABAGE study. * Follow-up at Reims hospital. Exclusion Criteria: \- Refusal to participate.
Where this trial is running
Reims
- Chu Reims — Reims, France (RECRUITING)
Study contacts
- Study coordinator: Sara BARRAUD, Dr.
- Email: sbarraud@chu-reims.fr
- Phone: 03.10.73.63.82
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Type1diabetes, Vascular complication, Diabetic retinopathy, Diabetic nephropathy, Diabetic neuropathy, Cardio-vascular events, Advanced Glycation End Products, AGE